Semaglutide safety in dialysis patients

This article is for educational purposes only. Nothing here is medical advice. Dialysis patients carry a high burden of comorbidity and require individualised clinical management. Any decision about continuing or adjusting semaglutide therapy in the context of kidney failure must be made with the clinicians who know the patient's full picture.

The question on the table

When a person with type-2 diabetes initiates dialysis, the prescribing calculus around most medicines shifts. Kidney failure alters drug clearance, fluid balance, and cardiovascular risk in ways that force a fresh look at every item on the medication list. For GLP-1 receptor agonists such as semaglutide, that question had no good answer until 2026, when a pooled individual-level analysis across four large randomised trials reported the first systematic safety data for this specific transition point^[1].

What Klein et al. found

The original analysis by Klein, Menacher, Buse, Mann, Tuttle, and colleagues, published in Diabetes Care in June 2026, drew on data from 34,064 trial participants across the SUSTAIN, PIONEER, STEP, and FLOW programmes^[1]. Of those, 165 participants initiated dialysis during the trials and continued on treatment. Among that small but clinically important subset, serious adverse events occurred in 45% of those receiving semaglutide compared with 57% on placebo. The authors concluded that continuation of semaglutide after dialysis initiation appears safe, and called for dedicated efficacy testing of cardiovascular outcomes and mortality reduction in dialysis patients.

Two caveats the authors themselves flagged are worth naming clearly. First, 165 participants is a small number for drawing definitive safety conclusions; the confidence intervals around the serious adverse event rates are wide. Second, the analysis was post-hoc and observational within randomised trial populations, not a prospective trial designed to answer the dialysis question. The finding is hypothesis-generating, not confirmatory.

The correspondence exchange

A comment published in the same journal in September 2026 raised methodological questions about the Klein et al. analysis^[2]. The authors of the response, which included Menacher, Mayrdorfer, Lingvay, and Klein, addressed those concerns directly in the same issue^[3]. The details of the methodological dispute are technical, but the exchange illustrates the normal way science refines a finding. The Klein team stands behind the core conclusion while acknowledging the limitations inherent in any post-hoc subgroup analysis.

What both sides agree on: there is no prospective randomised trial that has specifically enrolled dialysis patients with type-2 diabetes to test semaglutide safety and efficacy. The Klein pooled analysis is the best available evidence for now, and both the commenters and the original authors say it warrants follow-up rather than settlement.

Where the FLOW trial fits

The FLOW trial, published in the New England Journal of Medicine in 2024, is the largest prospective evidence base for semaglutide and kidney outcomes^[4]. Across 3,533 participants with type-2 diabetes and chronic kidney disease, semaglutide reduced the primary composite kidney endpoint by 24% (hazard ratio 0.76) and lowered all-cause mortality risk by 20% compared with placebo. Serious adverse events were lower in the semaglutide group: 49.6% versus 53.8%.

FLOW enrolled patients with chronic kidney disease but not patients already on dialysis. The trial stopped early at a pre-specified interim analysis for efficacy, which is one reason the data on the transition from CKD to dialysis are thin. Klein et al. used FLOW as one of the four source trials in their pooled analysis, making it the most rigorous upstream data source for the dialysis subgroup question^[1].

Why dialysis patients are a distinct population

Dialysis removes small-molecule drugs with each session, but semaglutide is a large peptide bound to albumin and is not meaningfully cleared by dialysis. That pharmacokinetic detail matters: drug exposure in a dialysis patient taking semaglutide is not substantially different from exposure in a patient with preserved kidney function taking the same dose. This is one reason the Klein team's finding of no obvious safety signal is plausible, even though the population is at high baseline risk.

A 2025 network meta-analysis of GLP-1 receptor agonists in non-dialysis CKD patients found that semaglutide was associated with the least kidney function harm of the agents reviewed, a finding consistent with the FLOW data^[5]. Whether the same pharmacological profile holds once patients progress to dialysis dependence is what the Klein analysis tries, with acknowledged limitations, to begin answering.

What remains unknown

The question of whether semaglutide reduces cardiovascular events or mortality in dialysis patients has not been answered by any prospective trial. Dialysis patients have cardiovascular mortality rates far higher than the general population, which is exactly why the question matters. The Klein team's call for a dedicated efficacy trial is the appropriate scientific response to a reassuring but limited safety signal.

Drug-drug interactions, nutritional status, and fluid management in dialysis patients add layers of complexity that the pooled analysis cannot fully characterise. Any prescriber considering semaglutide continuation after dialysis initiation is working with incomplete evidence, and the appropriate weight to place on the Klein findings versus individual patient factors is a clinical judgment, not something a pooled post-hoc analysis can resolve.

The take-away for patients and clinicians

The 2026 Diabetes Care correspondence exchange is a piece of the scientific process working as it should: a finding gets published, it receives public scrutiny, and the authors defend or update their position. For patients on semaglutide who face dialysis initiation, the practical message is that there is now more evidence than before but still not a definitive prospective trial. The decision to continue, adjust, or stop semaglutide at dialysis initiation should be made jointly with a nephrologist and a diabetologist, who can weigh the emerging safety data against the individual patient's cardiovascular risk, nutritional status, and treatment goals. Do not adjust any prescribed medicine on the basis of this article.